Patent ID: 6329385
Filing Date: 2001-12-11
Classification: A61P,C07D

Abstract:
A method of treating a disease associated with aberrant leukocyte recruitment and/or activation mediated by chemokine receptor function, comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula: ##STR17##or physiologically acceptable salt thereof, wherein:n is an integer from one to four;M is >CR.sup.1 R.sup.2 ;R.sup.1 is --H, --OH, an aliphatic group, --O-(aliphatic group), --O-(substituted aliphatic group), --SH, --S-(aliphatic group), --S-(substituted aliphatic group), --OC(O)-(aliphatic group), --O--C(O)-(substituted aliphatic group), --C(O)O-(aliphatic group), --C(O)O-(substituted aliphatic group), --CN, --COOH, --CO--NR.sup.3 R.sup.4 or --NR.sup.3 R.sup.4 ; or R.sup.1 is a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M;R.sup.2 is --OH, an acyl group, a substituted acyl group, --NR.sup.5 R.sup.6, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently --H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; orR.sup.1 and R.sup.2, R.sup.3 and R.sup.4, or R.sup.5 and R.sup.6 taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring;said acyl group is an aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl or aromatic sulfonyl;Z is represented by the structural formula: ##STR18##wherein:X.sub.1 is --S--, --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --S--, --S--CH.sub.2 --, --O--CH.sub.2 --, --CH.sub.2 --O--, --NR.sub.c --CH.sub.2 --, --CH.sub.2 --NR.sub.c --, --SO--CH.sub.2 --, --CH.sub.2 --SO--, --S(O).sub.2 --CH.sub.2 --, --CH.sub.2 --S(O).sub.2 --, --CH.dbd.CH--, --NR.sub.c --CO-- or --CO--NR.sub.c --; wherein:R.sub.c is --H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group or a substituted benzyl group; andRing A and Ring B are independently substituted or unsubstituted.